New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
15:11 EDTABTEarnings Preview: Abbott's Q4 will be last to include proprietary pharma
Abbott Laboratories (ABT) is scheduled to report Q4 earnings before the market open on Wednesday January 23, with a conference call scheduled for 9:00 am ET. Abbott is engaged in the discovery, development, manufacture, and sale of health care products worldwide. The company recently separated its proprietary pharmaceutical business into AbbVie, an independent company... EXPECTATIONS: Analysts are looking for EPS of $1.50 on revenue of $10.58B, according to First Call. The consensus range for EPS is $1.47-$1.53 on revenue of $10.40B-$10.76B... LAST QUARTER: Abbott reported Q3 EPS of $1.30 against estimates of $1.28 on revenue of $9.77B against estimates of $9.93B. On its Q3 earnings conference call the company said it was too early to give FY13 guidance... STREET RESEARCH: On January 11, Barclays initiated Abbott with an Equal Weight and a $35 price target. Earlier in January, Deutsche Bank downgraded Abbott to Hold from Buy with a $33 price target citing valuation following the spin-off of AbbVie, while Wells Fargo in a research note on January 2 said Abbott shares are attractive following the spin-off, citing significant margin expansion opportunities. Wells Fargo gave a valuation range on Abbott shares of $33-$34 to reflect the spin-off... PRICE ACTION: Shares of Abbott traded in an upward trajectory in 2012 from approximately $56.50 to a high of approximately $72 reached in mid-October. Abbott has traded in a range of approximately $31.64 to $33.88 since the company announced the completion of the spin-off on January 2.
News For ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
12:35 EDTABTMylan completes acquisition of assets from Abbott
Mylan N.V. and Mylan (MYL) announced the successful completion of the acquisition of Abbott Laboratories' (ABT) non-U.S. developed markets specialty and branded generics business. Under the previously announced terms of the transaction agreement, Abbott received 110M shares of Mylan N.V., resulting in former Mylan shareholders now owning approximately 78% of Mylan N.V. and Abbott now owning approximately 22% of Mylan N.V. Mylan Inc. and Abbott's non-U.S. developed markets specialty and branded generics business have been reorganized under Mylan N.V., a new public company organized in the Netherlands. Mylan N.V. will be led by the former Mylan Inc. executive team. The company will trade on Nasdaq under the ticker symbol MYL.
February 20, 2015
07:08 EDTABTAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use